文献速递妇科肿瘤

安罗替尼联合尼拉帕利治疗铂耐药复发卵巢癌的疗效与安全性

[The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2024-01-01

该研究纳入35例既往接受过二线及以上化疗的铂耐药复发卵巢癌患者,给予安罗替尼联合尼拉帕利治疗,主要终点为无进展生存时间(PFS)。结果显示客观有效率(ORR)为40.0%,疾病控制率(DCR)为77.1%,中位PFS为6.5个月,中位总生存时间(OS)为18.4个月,常见治疗相关不良反应为乏力、骨髓抑制及高血压,无治疗相关死亡。

要点

  • 安罗替尼联合尼拉帕利治疗35例铂耐药复发卵巢癌,ORR为40.0%,DCR为77.1%。
  • 中位PFS为6.5个月,中位OS为18.4个月。
  • 常见治疗相关不良反应为乏力(85.7%)、骨髓抑制(85.7%)及高血压(74.3%),无治疗相关死亡。

核心结论

  • 安罗替尼联合尼拉帕利在铂耐药复发卵巢癌患者中显示出较好的疗效和可耐受的安全性。

研究设计与样本

  • 选取2019年9月至2021年10月中国医学科学院肿瘤医院深圳医院收治的35例经病理确诊的铂耐药复发卵巢癌患者,既往接受过二线及以上化疗。
  • 所有患者均给予安罗替尼联合尼拉帕利治疗,主要观察终点为PFS,次要观察指标为OS、ORR、DCR及安全性。
  • 生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。

主要发现

  • 35例患者中部分缓解14例、病情稳定13例、疾病进展8例,ORR为40.0%(95%CI:22.9%~57.1%),DCR为77.1%(95%CI:62.9%~91.4%)。
  • 中位随访时间为18.9个月(6.9~32.2个月),中位PFS为6.5个月(95%CI:5.4~7.7个月),中位OS为18.4个月(95%CI:16.1~20.8个月)。
  • 多因素回归分析提示美国东部肿瘤协作组功能状态评分、国际妇产科联盟分期、乳腺癌易感基因(BRCA)突变是PFS的独立影响因素(均P<0.05)。
  • 首次接受PARP抑制剂治疗含BRCA突变的患者PFS(15.0个月)较未接受过PARP抑制剂治疗且不含BRCA突变的患者长(6.0个月,P=0.029)。
  • 常见治疗相关不良反应为乏力(85.7%,30/35)、骨髓抑制(85.7%,30/35)及高血压(74.3%,26/35),无治疗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: To investigate the efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant ovarian cancer. Methods: Thirty-five patients with pathological confirmed platinum-resistant ovarian cancer who experienced progression after receiving at least two lines of standard treatment were eligible. All of them were treated with anlotinib combined with niraparib between September 2019 and October 2021. The primary endpoint was progression-free survival (PFS). The second endpoints included overall survival, objective response rate (ORR), disease control rate (DCR) and safety. Survival analysis was performed using the Kaplan-Meier method and Log-rank test, and influence factor analysis was performed using Cox proportional risk regression models. Results: The best overall response showed that partial response was observed in 14 patients, stable disease was noted within 13 patients, and progressive disease was found in 8 patients. Therefore, the ORR and DCR of these 35 patients were 40.0% (95% CI:22.9%-57.1%) and 77.1% (95% CI:62.9%-91.4%), respectively. The median follow-up duration was 18.9 months (6.9-32.2). The median PFS was 6.5 months (95% CI:5.35-7.66). Multivariate Cox regression analysis for PFS indicated that age, Eastern Cooperative Oncology Group performance status (ECOG PS) score, International Federation of Gynecology and Obstetrics (FIGO) stage, and BRCA mutation status were independent factors influencing PFS (P<0.05). Additionally, the PFS in patients with BRCA mutation who have never received PARP inhibitor treatment was significantly longer than that in patients without BRCA mutation who have been exposed to prior PARPi treatment (15.0 vs 6.0 month, P=0.029). The most common treatment-related adverse reactions were fatigue (85.7%), hematologic toxic (85.7%) and hypertension (74.3%). There were no treatment-related deaths. Conclusion: Anlotinib combined with niraparib shows a promising efficacy and tolerable safety in platinum-resistant ROC patients. 目的: 探讨安罗替尼联合尼拉帕利治疗铂耐药复发卵巢癌的有效性和安全性。 方法: 选取2019年9月至2021年10月中国医学科学院肿瘤医院深圳医院收治的35例铂耐药复发卵巢癌患者,既往接受过二线及以上化疗。所有患者均给予安罗替尼联合尼拉帕利治疗,主要观察终点为无进展生存时间(PFS),次要观察指标为总生存时间(OS)、客观有效率(ORR)、疾病控制率(DCR)及安全性。生存分析采用Kaplan-Meier法和Log rank检验,影响因素分析采用Cox比例风险回归模型。 结果: 35例接受治疗的患者中,部分缓解14例,病情稳定13例,疾病进展8例,ORR为40.0%(95% CI:22.9%~57.1%),DCR为77.1%(95% CI:62.9%~91.4%)。中位随访时间为18.9个月(6.9~32.2个月),中位PFS为6.5个月(95% CI:5.4~7.7个月),中位OS为18.4个月(95% CI:16.1~20.8个月)。多因素回归分析结果提示,美国东部肿瘤协作组功能状态评分、国际妇产科联盟分期、乳腺癌易感基因(BRCA)突变是PFS的独立影响因素(均P<0.05)。首次接受PARP抑制剂治疗含BRCA突变的患者PFS(15.0个月)较未接受过PARP抑制剂治疗且不含BRCA突变的患者长(6.0个月,P=0.029)。常见的治疗相关不良反应为乏力(85.7%,30/35)、骨髓抑制(85.7%,30/35)及高血压(74.3%,26/35)。 结论: 安罗替尼联合尼拉帕利治疗能延长铂耐药复发卵巢癌患者的生存时间,且安全性可控。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang M, Wang JJ, Deng SQ, et al. [The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 39034805. doi:10.3760/cma.j.cn112152-20231024-00224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。